JPMorgan Claverhouse (LON:JCH – Get Free Report) insider Graham Oldroyd bought 5,330 shares of the company’s stock in a transaction that occurred on Monday, October 26th. The stock was purchased at an average price of GBX 976 per share, with a total value of £52,020.80.
JPMorgan Claverhouse Trading Down 0.4%
JPMorgan Claverhouse stock traded down GBX 4 during mid-day trading on Tuesday, hitting GBX 940. The company’s stock had a trading volume of 61,173 shares, compared to its average volume of 85,265. The company has a debt-to-equity ratio of 5.90, a current ratio of 14.76 and a quick ratio of 67.67. The business has a 50 day moving average price of GBX 950.44 and a 200-day moving average price of GBX 914.10. The stock has a market cap of £511.46 million, a price-to-earnings ratio of 5.88 and a beta of 1.01. JPMorgan Claverhouse has a 12 month low of GBX 804 and a 12 month high of GBX 986.
JPMorgan Claverhouse (LON:JCH – Get Free Report) last posted its earnings results on Thursday, August 13th. The investment trust reported GBX 23.25 earnings per share (EPS) for the quarter. JPMorgan Claverhouse had a return on equity of 17.56% and a net margin of 95.11%.
About JPMorgan Claverhouse
Great British dividends
Established in 1963, the JPMorgan Claverhouse Investment Trust provides investors with direct access to the long-term growth and income potential of UK stock market. The trust is committed to investing in attractively valued, high-quality UK companies with the ability to deliver consistent and growing dividends. With a heritage spanning over six decades, Claverhouse is distinguished by its disciplined investment approach and dedication to shareholder returns.
Expertise
The trust is managed by a team of seasoned UK equity portfolio managers—Anthony Lynch, Katen Patel, and Callum Abbot—each with more than 13 years of industry experience.
Featured Articles
- Five stocks we like better than JPMorgan Claverhouse
- Approaching Earnings Season, Are Pure Play Quantum Stocks Still a Good Bet?
- Lockheed Martin’s F-35 Deal Could Change How Wall Street Values the Stock
- Merck and Moderna’s Cancer Vaccine Worked—Who Gets Paid?
- Intel’s $155 Price Target Raises a Bigger Question About Its Turnaround Potential
Receive News & Ratings for JPMorgan Claverhouse Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for JPMorgan Claverhouse and related companies with MarketBeat.com's FREE daily email newsletter.
